• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Lupin launches Zileuton extended-release tablets

expresspharmaAugust 12, 2020

Tag: lupin , Zileuton , FDA

Lupin announced the launch of Zileuton extended-release tablets, 600 mg, having received an approval from the United States Food and Drug Administration (US FDA) earlier. The product would be manufactured at Lupin’s Nagpur facility, India.

Zileuton extended-release tablets, 600 mg, is the generic equivalent of Zyflo CR extended-release tablets, 600 mg, of Chiesi USA, and is indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.

Zileuton extended-release tablets had annual sales of approximately $40 million in the US (IQVIA MAT June 2020).


Previous:Daewoong Pharma gets CDSCO nod to test anti-parasite drug for COVID-19

Next:Roche gets US FDA approval for Evrysdi to treat spinal muscular atrophy

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Lupin launches Zileuton extended-release tablets | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Nabumetone (FDA)

Nabumetone (FDA)
Vecuronium (FDA)

Vecuronium (FDA)
Irinotecan Hcl trihudrate (FDA)

Irinotecan Hcl trihudrate (FDA)
Etoposide( FDA)

Etoposide( FDA)
High quality Stability Chamber(FS/CFS Series:FDA)

High quality Stability Chamber(FS/CFS Series:FDA)
Vecuronium Bromide(FDA)

Vecuronium Bromide(FDA)
Mitomycin ( FDA)

Mitomycin ( FDA)
Tobramycin base( FDA)

Tobramycin base( FDA)
Ribavirin (FDA)

Ribavirin (FDA)
Mesnaum (FDA)

Mesnaum (FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service